Comparative Pharmacology
Head-to-head clinical analysis: BRIMONIDINE TARTRATE AND TIMOLOL MALEATE versus CARTEOLOL HYDROCHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BRIMONIDINE TARTRATE AND TIMOLOL MALEATE versus CARTEOLOL HYDROCHLORIDE.
BRIMONIDINE TARTRATE AND TIMOLOL MALEATE vs CARTEOLOL HYDROCHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Brimonidine tartrate is a selective alpha-2 adrenergic receptor agonist that reduces aqueous humor production and increases uveoscleral outflow. Timolol maleate is a non-selective beta-adrenergic receptor antagonist that decreases aqueous humor production by blocking beta-2 receptors in the ciliary epithelium.
Non-selective beta-adrenergic receptor antagonist (beta-blocker) with intrinsic sympathomimetic activity (ISA) and weak local anesthetic (membrane-stabilizing) activity. Reduces intraocular pressure by decreasing aqueous humor production.
One drop in the affected eye(s) twice daily (approximately 12 hours apart).
Ophthalmic: Instill 1 drop of 1% or 2% solution into affected eye(s) twice daily. Oral: 2.5 mg to 5 mg once daily; may increase to 10 mg once daily if needed. Maximum dose 10 mg daily.
None Documented
None Documented
Brimonidine: ~2.9 hours (terminal) after ophthalmic administration. Timolol: ~4 hours (terminal); clinically, systemic exposure is low due to topical route.
Terminal elimination half-life is 5-6 hours in patients with normal renal function; may extend to 24-36 hours in severe renal impairment.
Brimonidine: ~74% renal (unchanged and metabolites), ~22% fecal. Timolol: ~20% renal (unchanged), ~80% hepatic metabolism with biliary and fecal elimination.
Renal excretion of unchanged drug and active metabolite (8-hydroxycarteolol) accounts for 50-70% of elimination. Biliary/fecal excretion is minimal (<10%).
Category A/B
Category C
Beta-Blocker
Beta-Blocker